BARDA Enlists Nanotherapeutics to Produce Drugs Vulnerable to Shortage

Published on: 

The new project will increase fill/finish manufacturing capacity for select products on FDA’s Drug Shortage Index.


Through the use of federal funds, Nanotherapeutics will increase its manufacturing capacity for the fill/finish of numerous medications that are in short supply, the company announced on July 9, 2015. The company received two task orders from The United States Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA) Fill-Finish Manufacturing Network’s (FFMN) Pilot Production program that address the manufacture of products with limited commercial availability.


BARDA has solicited Nanotherapeutics’ help on previous projects, including a contract to provide fill/finish services for influenza vaccines and other publicy health emergency products in 2013, around the time the FFMN was founded. The FEMN was created in 2013 to expedite the production of the development of medical countermeasures and the influenza vaccine in the occurrence of a pandemic. Nanotherapeutics was also previously awarded a task order from BARDA for the fill/finish of Mapp Biopharmaceutical’s ZMapp to treat Ebola.

Source: Nanotherapeutics